Pipeline Insight: Disease Modification In Rheumatoid Arthritis

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2005-10-05

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The treatment of Rheumatoid Arthritis (RA) has been rapidly evolving over the last decade. Currently, the newer targeted biologic therapies against specific molecules involved in the pathogenesis of RA reduce side-effects, but cheaper traditional therapies are still used in the majority of patients. DMARDs are a rapidly changing growth area of the RA market showing high innovation and competition.


Scope

  • Detailed pipeline analysis for key products in a specific RA indication, plus drug sales forecasts to 2014
  • Overview of patient potential, segmentation by indication and unmet needs in RA across the seven major markets
  • Benchmarking of key clinical and company attractiveness of the late-Phase pipeline products
  • Detailed clinical trial information and opinion from key thought leaders


    • Report Highlights
    If biologic products continue their exponential uptake the market could reach over US$11 billion by 2014. However, this would put an incredible strain on the financial resources of the key markets, as most growth is driven by high biologic pricing and it is likely that restrictions will be put in place to reduce the cost to payers.

    Competition will be fierce between the next DMARDs to be launched, Rituxan/MabThera (rituximab) and Orencia (abatacept). Rituximab's promising dosing and use in cancer indications gives it an advantage over abatacept's novel co-stimulatory modulator. Both will initially be competing for anti-TNF failure patients.

    The Roche, Biogen Idec and Genentech partnership looks set to dominate future biologic treatments in RA. Roche's financial clout and Japanese partnership with Chugai compliments Biogen Idec's immunology innovation and Genentech's protein-based specialist knowledge to place the products from this group at an immediate advantage.


    Reasons to Purchase

  • Understand why pricing restraint is necessary for the continued exponential uptake and commercial growth of the biologic DMARDs
  • Quantify the future size and potential of the market for novel treatments in the RA indication in each of the seven major markets
  • Use analysis of the key molecular targets under investigation to find gaps in the market for your product

    • Table of Contents

    Other users found this report page using the following search terms: rheumatoid arthritis autoimmune arthritis rheumatoid cnto 136 pipeline ra cimzia sales actemra cnto136

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.